Novel Therapies for Type 2 Diabetes Mellitus.
- Author:
Jung Min KO
1
Author Information
1. Department of Medical Genetics, Ajou University College of Medicine, Suwon, Korea. jmko@ajou.ac.kr
- Publication Type:Review
- Keywords:
Incretin;
Glucagon like polypeptides;
Dipeptidyl peptidase IV inhibitors;
Amylin;
Endogenous cannabinoids;
Diabetes Mellitus;
Type 2
- MeSH:
Adult;
Blood Glucose;
Diabetes Mellitus;
Diabetes Mellitus, Type 2;
Dipeptidyl Peptidase 4;
Dipeptidyl-Peptidase IV Inhibitors;
Glucagon-Like Peptides;
Homeostasis;
Humans;
Incretins;
Insulin Resistance;
Islet Amyloid Polypeptide
- From:Journal of Korean Society of Pediatric Endocrinology
2009;14(1):11-18
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Type 2 diabetes mellitus (T2DM) is a progressive disorder caused by a combination of insulin resistance and betacell dysfunction. The role of new hormones and systems in maintaining blood glucose homeostasis has recently been recognized. This recognition has led to the development of several novel classes of medications, including the incretin mimetic agents (glucagon like polypeptide-1 analogs and dipeptidyl peptidase IV inhibitors), the amylin analog and the endocannabinoid-1 receptor blocker. This review looks at these new agents in terms of their mode of action, pharmacokinetics and use in clinical practice. The new agents offer treatment options in select adult patients now, however, the efficacy and the safety has to be evaluated thoroughly by long term studies before the application to pediatric patients.
